Double Digit Gains And Counting For These Two Biotechs

Two major catalysts are converging in biotech as we speak.

And it could mean big things for those with positions in the sector throughout the rest of 2018.

For starters we have a slew of FDA trial dates coming up over the next few months.

FDA trials are a make or break moment for biotechs. And if a company impresses during their trial, share values of that company typically skyrocket.

There are literally hundreds of FDA trials scheduled for the second half of this year.

Another catalyst we expect to also play out this year is an increased number of mergers and acquisitions.

The panel on CNBC’s Squawk Box this morning noted that in 2018 many large companies will use the extra cash they’ve received from Trump’s tax cuts to buy out their competition.

And this will be especially true in biotech.

These two catalysts could mean big money in biotech in Q3 and Q4.

Today we’ll look at how these catalysts are playing out with two stocks we’ve recently profiled in Tech Profits Daily.

The Dawn of a New Age In Medical Robotics

Advances in artificial intelligence and robotics are accelerating faster than we could have ever imagined.

For tech investors this is opening up a whole new world of profit potential.

The money is pouring into this industry at an unbelievable rate and it’s only natural that many companies in this space will see nice runs in stock value over the coming months and years.

If you haven’t purchased your ticket for the medical robotics gravy train yet, you’ll seriously want consider doing so soon.

Take for instance one of the companies we recently profiled for our Tech Profits watchlist, Intuitive Surgical (NASDAQ: ISRG).

ISRG is a leading medical robotics manufacturer. Their most recognizable product is the Da Vinci surgical robot. But the company has a many other advanced medical devices on the market and in its pipeline as well.

We first mentioned ISRG as a company to watch on February 14.

At the time the stock was trading for $397.51. As I write today, ISRG trades for $466.65. An increase of over 17% in two months.

But this is only one of many prime examples of gains you can capture in biotech right now.

Now let’s look at how one of our small-cap watchlist stocks is doing.

Your Slice Of An $8 Billion Pie

Immunotherapy has become a multi-billion dollar market. And when a company makes a splash in this space the profits quickly follow.

This is exactly what we’re seeing with another one of our watchlist stocks, Rigel Pharmaceuticals (NASDAQ: RIGL).

We first mentioned RIGL on Feb 14 at a price of $3.15. As I write today the stock trades at $3.78, an easy 20% gain in under 60 days.

Even better, RIGL had one of its first-in-class immunotherapies, Tavalisse, approved by the FDA in April.

Currently, the stock is trading at 16% discount from its 200-day high of $4.50 meaning there’s still room for it to grow.

And if sales are strong for its new immunotherapy treatment there’s no reason why more gains shouldn’t follow.

To be clear, these stocks are not official recommendations. But they are companies that have shown and are still showing a lot of promise.

If you do your own research and like what you see, perhaps you’ll want to make a move.

Just remember, never bet more money than you’re willing to lose. And ALWAYS do you own research to make sure any moves meet your specific financial goals.

With that said we’ll have more biotechs worth considering soon.

Happy trading!

For Technology Profits Daily,

Sean McCloskey

Sean McCloskey
Managing Editor, Technology Profits Daily

You May Also Be Interested In:

Sean McCloskey

Sean McCloskey is the managing editor of the Technology Profits Daily and Mike Burnick’s Wealth Watch e-letters. He has been with Seven Figure Publishing since 2017.

View More By Sean McCloskey